Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

Inclusion Criteria: * Patients with recurrent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) * Prior treatment with at least 2 systemic chemotherapy regimens for CLL * Life expectancy of \>3 months * Adequate liver and kidney function * Absolute neutrophil count ≥500/mm3; platelets ≥50,000/dL; hemoglobin ≥9 g/dL * Willing to use accepted method of contraception during the course of the study * Negative pregnancy test (females) * Written informed consent Exclusion Criteria: * Chemotherapy or radiotherapy within 4-6 weeks of the start of treatment (depending on the therapy) * Investigational drug within 30 days of the start of treatment * Uncontrolled intercurrent illness such as infection or cardiovascular disease * Pregnant or breastfeeding women * Subjects known to be HIV positive